DLB — Dolby Laboratories Balance Sheet
0.000.00%
- $6.59bn
- $5.90bn
- $1.27bn
- 93
- 49
- 65
- 79
Annual balance sheet for Dolby Laboratories, fiscal year end - September 27th, USD millions except per share, conversion factor applied.
2020 September 25th | 2021 September 24th | 2022 September 30th | 2023 September 29th | 2024 September 27th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 1,119 | 1,264 | 809 | 885 | 482 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 342 | 415 | 420 | 444 | 513 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 1,547 | 1,760 | 1,311 | 1,488 | 1,194 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 618 | 602 | 560 | 522 | 518 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 2,917 | 3,106 | 2,690 | 2,980 | 3,110 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 267 | 316 | 278 | 422 | 418 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 485 | 508 | 443 | 625 | 633 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 2,433 | 2,598 | 2,246 | 2,355 | 2,477 |
| Total Liabilities & Shareholders' Equity | 2,917 | 3,106 | 2,690 | 2,980 | 3,110 |
| Total Common Shares Outstanding |